California-based Azalea Therapeutics, a biotech promising to redefine precision genomic medicines in vivo, has announced its ...

According to Nova One Advisor, the global gene editing market size is calculated at USD 11.29 billion in 2025 and is expected ...

Chocolate prices have been rising due to complications in the supply chain, but Penn State researchers have made a ...

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

We have written about the promise of gene therapy to correct genetic disease many times. An exciting development happened ...

Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Investing.com -- Intellia Therapeutics (NASDAQ:NTLA) stock fell 19% after the market close Wednesday after the U.S. Food and Drug Administration (FDA) placed a clinical hold on the company’s Phase 3 ...

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed some of the first robust laboratory models of a ...

A researcher at the University of Houston finds management of diabetic ketoacidosis may center around reducing ketone levels ...

A new scalable technique enables the generation of human kidney organoids by integrating them into perfused pig kidneys.

Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...